Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Computational Statistics & Data Analysis
|
June 6, 2022
A study of longitudinal trends in time-frequency transformations of EEG data during a learning experiment
Joanna Boland, Donatello Telesca, Catherine Sugar, et al.
Statistics in Biosciences
|
December 22, 2025
Central Posterior Envelopes for Bayesian Longitudinal Functional Principal Component Analysis
Joanna Boland, Qi Qian, Donatello Telesca, et al.
Journal of Data Science : JDS
|
June 17, 2024
Central Posterior Envelopes for Bayesian Functional Principal Component Analysis
Joanna Boland, Donatello Telesca, Catherine Sugar, et al.
Diabetes & Metabolic Syndrome
|
August 17, 2025
Prevalence, treatment patterns, burden, and factors related to treatment failure with sodium-glucose cotransporter 2 inhibitor in adults with type 2 diabetes in the United States
Xi Tan, Yiwen Cao, Yan Wang, et al.
Infectious Diseases and Therapy
|
August 31, 2025
RSV Testing Patterns and Characteristics Associated with RSV Testing Among Adults Aged 50 Years or Older in the United States
David Singer, Emily K Horn, Yan Wang, et al.
Diabetes, Obesity & Metabolism
|
March 27, 2026
Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study
Michael G Nanna, Carlos Mena-Hurtado, Victoria Divino, et al.
American Journal of Preventive Cardiology
|
June 15, 2026
Association between semaglutide 2.4 mg and risk of cardiovascular events in people with overweight or obesity without atherosclerotic cardiovascular disease in the real-world: The SCORE - primary prevention study
Kim G Smolderen, Carlos Mena-Hurtado, Victoria Divino, et al.
Diabetes, Obesity & Metabolism
|
September 10, 2025
Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)
Kim G Smolderen, Carlos Mena-Hurtado, Zhenxiang Zhao, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Computational Statistics & Data Analysis
|
June 6, 2022
A study of longitudinal trends in time-frequency transformations of EEG data during a learning experiment
Joanna Boland, Donatello Telesca, Catherine Sugar, et al.
Statistics in Biosciences
|
December 22, 2025
Central Posterior Envelopes for Bayesian Longitudinal Functional Principal Component Analysis
Joanna Boland, Qi Qian, Donatello Telesca, et al.
Journal of Data Science : JDS
|
June 17, 2024
Central Posterior Envelopes for Bayesian Functional Principal Component Analysis
Joanna Boland, Donatello Telesca, Catherine Sugar, et al.
Diabetes & Metabolic Syndrome
|
August 17, 2025
Prevalence, treatment patterns, burden, and factors related to treatment failure with sodium-glucose cotransporter 2 inhibitor in adults with type 2 diabetes in the United States
Xi Tan, Yiwen Cao, Yan Wang, et al.
Infectious Diseases and Therapy
|
August 31, 2025
RSV Testing Patterns and Characteristics Associated with RSV Testing Among Adults Aged 50 Years or Older in the United States
David Singer, Emily K Horn, Yan Wang, et al.
Diabetes, Obesity & Metabolism
|
March 27, 2026
Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study
Michael G Nanna, Carlos Mena-Hurtado, Victoria Divino, et al.
American Journal of Preventive Cardiology
|
June 15, 2026
Association between semaglutide 2.4 mg and risk of cardiovascular events in people with overweight or obesity without atherosclerotic cardiovascular disease in the real-world: The SCORE - primary prevention study
Kim G Smolderen, Carlos Mena-Hurtado, Victoria Divino, et al.
Diabetes, Obesity & Metabolism
|
September 10, 2025
Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)
Kim G Smolderen, Carlos Mena-Hurtado, Zhenxiang Zhao, et al.
Page
of 1